BBO-8520

DEVELOPMENT STEP phase-1

SPONSOR MATRIX BridgeBio Oncology Therapeutics [BBOT]

MECHANISM TARGET KRAS

[THERAPEUTIC_PROFILE]

Target Indications

KRAS mutant NSCLC

Mechanism Abstract

A small molecule protein degrader

[3D_INTERACTIVE_CONFORMATION]

[3D_CONFORMATION_UNAVAILABLE • RETRIEVED_2D_BIOMATRIX]

[CLINICAL_TRIALS_REGISTRY]

TOTAL EXTRACTED1

RECRUITING STATUS1

COMPLETED RUNS0

REGISTRY & PHASE

TESTED CONDITION

STUDY TITLE & LIFECYCLE TIMELINES

STATUS

➔

P-1NCT06343402

Non-small Cell Lung CancerMetastatic Non-Small Cell Lung Cancer+4 more

N=350Est. Finish: 2031-09

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

recruiting

ENROLLMENT PATIENT CAPACITY350 Patients(estimated)

ESTIMATED RUN COMPLETION MILESTONES

Start Date:2024-05-22(actual)

Primary End:2031-04(estimated)

Study Finish:2031-09(estimated)

OFFICIAL PROTOCOL TITLE

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

[INVESTIGATORS_&_FACILITY_ROSTER]

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)CONTACT — TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)